OTCMKTS:ELXMF Nova Eye Medical (ELXMF) Stock Price, News & Analysis $0.01 0.00 (0.00%) As of 06/5/2026 Add Compare Share Share Stock Analysis Stock AnalysisChartBuy This Stock About Nova Eye Medical Stock (OTCMKTS:ELXMF) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Nova Eye Medical alerts:Sign Up Key Stats Today's Range$0.0143▼$0.014350-Day Range$0.0019▼$0.014352-Week Range$0.0019▼$0.0143VolumeN/AAverage Volume75,600 shsMarket CapitalizationN/AP/E Ratio1.96Dividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Nova Eye Medical (OTCMKTS: ELXMF) is a medical device company focused on developing advanced ophthalmic diagnostic solutions for ocular surface diseases, particularly dry eye. Its flagship Ocular Surface Analyzer integrates high-resolution imaging with proprietary algorithms to provide quantitative assessments of tear film stability, lipid layer thickness and meibomian gland function. By offering objective, reproducible data, the system is designed to support eye care professionals in early detection and accurate diagnosis of dry eye disease. The Nova Eye Medical platform combines specialized hardware and custom software to automate key measurements such as non-invasive tear breakup time, tear meniscus height and meibography. Automated image analysis and report generation streamline clinical workflows, enabling practitioners to monitor treatment efficacy and adjust therapeutic strategies based on precise ocular surface metrics. The company continues to refine its software suite to expand diagnostic capabilities and enhance user experience. Nova Eye Medical distributes its products through a network of direct sales and third-party distributors in North America and select European markets. With an emphasis on personalized treatment monitoring and early intervention, the company aims to address the growing global demand for objective ocular surface diagnostics. Management comprises industry professionals with backgrounds in ophthalmic instrumentation, regulatory affairs and device commercialization as Nova Eye Medical pursues broader clinical adoption.AI Generated. May Contain Errors. Read More Receive ELXMF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nova Eye Medical and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ELXMF Stock News HeadlinesNova Eye Medical Limited (ELXMF) Q3 2026 Earnings Call TranscriptMay 5, 2026 | seekingalpha.comNova Eye Medical (ASX:EYE) Is In A Good Position To Deliver On Growth PlansFebruary 4, 2026 | finance.yahoo.comUncle Sam now owns 9.9% of IntelOn August 22, 2025, the U.S. government became one of Intel's largest shareholders - converting CHIPS Act grants into a 9.9% equity stake worth 8.9 billion dollars at 20.47 per share. Weeks earlier, the DoD took a 15% stake in rare-earth miner MP Materials, and the DOE followed with a 5% stake in Lithium Americas alongside a 2.23 billion dollar loan. Federal equity ownership in semiconductors, rare earths, and lithium - at this scale - hasn't happened since World War II. Porter Stansberry says the rules of investing are changing, and the stocks positioned to win this realignment aren't the ones the financial press is covering.June 10 at 1:00 AM | Porter & Company (Ad)Nova Eye Medical Limited (ELXMF) Q2 2026 Earnings Call TranscriptFebruary 2, 2026 | seekingalpha.comNova Eye Medical Achieves Record FY25 Revenue with Strong US GrowthAugust 27, 2025 | msn.comNova Eye Medical Director Increases ShareholdingAugust 5, 2025 | tipranks.comNova Eye Medical Hosts Investor Webinar to Discuss Ophthalmic InnovationsJuly 7, 2025 | tipranks.comNova Eye Medical Achieves Record Revenues in FY25July 7, 2025 | tipranks.comSee More Headlines ELXMF Stock Analysis - Frequently Asked Questions How have ELXMF shares performed this year? Nova Eye Medical's stock was trading at $0.0019 at the beginning of 2026. Since then, ELXMF stock has increased by 652.9% and is now trading at $0.0143. How do I buy shares of Nova Eye Medical? Shares of ELXMF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today6/10/2026Next Earnings (Estimated)8/26/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Medical Devices Sub-IndustryN/A Current SymbolOTCMKTS:ELXMF CIKN/A Webwww.ellex.com Phone61 8 7074 8200FaxN/AEmployees301Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E Ratio1.96 Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A Beginner's Guide To Retirement StocksClick the link to see MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (OTCMKTS:ELXMF) was last updated on 6/10/2026 by MarketBeat.com Staff. From Our PartnersHe Called NVIDIA at $1.10 – Now He Says, “SELL”The analyst who called NVIDIA at $1.10 now says sell. According to Alexander Green, Chief Investment Strategis...The Oxford Club | SponsoredYour name isn't on our protected list yetI checked our download records for "The Big Beautiful Bubble Report" and didn't see your name. That concern...American Alternative | SponsoredI was right about SpaceXJeff Brown predicted Bitcoin before it climbed as high as 52,400%, Tesla before 2,150%, and Nvidia before 32,0...Brownstone Research | SponsoredThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Be...Banyan Hill Publishing | SponsoredTrump Is Eyeing the Biggest Monetary Shift Since NixonOn August 15, 1971, Nixon ended the Bretton Woods agreement and untethered the dollar from gold. Since that ni...Americas Gold Company | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredTesla. SolarCity. Twitter. This $4 stock is next.Elon Musk has a clear pattern: when a supplier becomes mission-critical, he acquires it. He bought SolarCity f...Behind the Markets | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nova Eye Medical Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Nova Eye Medical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.